What were the key takeaways from CorMedix's earnings call?

Did CorMedix beat or miss consensus estimates last quarter?

What is CorMedix's latest dividend and current dividend yield?

What is CorMedix's gross profit margin?

What guidance did CorMedix's management provide for the next earnings period?

What is the market's earnings forecast for CorMedix next quarter?

What were the key takeaways from CorMedix’s earnings call?

What factors drove the changes in CorMedix's revenue and profit?

- **Revenue Growth**: 2025 pro forma revenue $401.3M, driven by Melinta acquisition and DefenCath $258.8M sales.
- **2026 Guidance**: DefenCath $150M-$170M (front-loaded), full-year revenue $300M-$320M, EBITDA $100M-$125M.
- **Strategic Momentum**: Phase III REZZAYO data Q2 2026, Medicare Advantage contracting discussions, and inpatient DefenCath expansion opportunities.
- **Financial Strength**: $148.5M cash balance, share buyback program active, and operating leverage from 200+ employee base.


**【Management Opening Remarks】**
- The call was led by CEO Joseph Todisco, joined by EVPs Elizabeth Hurlburt (COO), Susan Blum (CFO), and other executives. 
- Participants were reminded of forward-looking statement risks and non-GAAP financial measures.

**【CEO Summary】**
- **2025 Milestones**: DefenCath achieved $258.8M in net sales, and the Melinta acquisition was completed in Q3 with $35M in realized synergies by Q4.
- **2026 Outlook**: 
  - DefenCath guidance: $150M-$170M (front-loaded due to TDAPA add-on transition)
  - Full-year revenue: $300M-$320M; Adjusted EBITDA: $100M-$125M
  - 2027 DefenCath guidance: $100M-$125M (based on current pricing assumptions)
- **Strategic Focus**: 
  - Finalizing 2026 supply pricing with top customers
  - Pursuing Medicare Advantage contracts
  - Promoting REZZAYO (Phase III ReSPECT data expected Q2 2026) and inpatient DefenCath opportunities

**【CFO Financial Commentary】**
- **Q4 2025 Results**: 
  - Net revenue: $128.6M (YoY +120%, driven by Melinta portfolio contribution)
  - Adjusted EBITDA: $77.2M (in-line with guidance)
  - Cash balance: $148.5M (supporting share buybacks and growth initiatives)
- **2025 Full Year**: 
  - Pro forma revenue: $401.3M (includes Melinta)
  - Operating expenses: $48.2M (Q4, reflecting integration costs)

**【Q&A Highlights】**
- **DefenCath Pricing**: Negotiations with top customers for 2026/2027 pricing; 2027 CMS bundle adjustment could increase net selling price.
- **REZZAYO Phase III**: Top-line data expected Q2 2026; potential to reduce hospitalizations and drug-drug interactions.
- **TDAPA Extension**: Legislative progress uncertain; retroactive application possible if passed post-June 2026.
- **Melinta Portfolio**: MINOCIN ($50M+ sales) and VABOMERE ($30M+ sales) expected to grow 2-3% annually through targeted promotions.
- **Inpatient DefenCath**: Small volumes but high ASP; potential to expand with new customers if CMS clarifies reimbursement rules.


CorMedix Inc.(CRMD)-20260305-2025 Q4 Earnings call transcript

- **Record Q3 Performance**: $104.3M revenue, $108.6M net income, $71.8M EBITDA - all records.
- **Synergy Capture**: $30M of $35-45M annual synergies achieved ahead of schedule.
- **Pipeline Catalysts**: 
  - Rezeo phase 3 fungal prophylaxis data Q2 2026 ($2B TAM).
  - DefenCath TPN phase 3 completion 2026/27 ($750M TAM).
- **Post-TDAPA Strategy**: 
  - Medicare Advantage partnerships leveraging real-world evidence.
  - CMS ESRD rule expected Q1 2026 to set 2026/27 pricing.

**【CEO Opening Remarks】**
- **Acquisition Update**: Completed Melinta acquisition, achieving $30M of $35-45M annual synergies by end-2025. Rebranded as CorMedix Therapeutics with new logo.
- **Record Q3 Financials**: Revenue $104.3M (vs. $26.8M YoY), Net Income $108.6M, Adjusted EBITDA $71.8M.
- **Guidance Update**: Full-year 2025 revenue raised to $390-410M (from $375M), EBITDA to $220-240M (from $165-185M).
- **Pipeline Momentum**: 
  - Rezeo phase 3 fungal prophylaxis data expected Q2 2026; $2B TAM for immune-compromised patients.
  - DefenCath TPN phase 3 completion by end-2026/Q1 2027; $750M TAM.
  - Strategic Telfera investment ($12.8M Melinta contribution Q3) with 2026 phase 3 readout.

**【COO Clinical & Integration Update】**
- **Clinical Progress**: 
  - Rezeo phase 3 enrollment complete; interim data expected late 2025.
  - DefenCath TPN study expanding to Turkey; 2,000-patient real-world evidence interim results due Q4.
- **Integration Milestones**: 
  - All functional teams unified; systems integration on track for 2026.
  - Transitioning legacy Melinta sales to internal team by Q1 2026.

**【CFO Financial Review】**
- **Revenue Breakdown**: DefenCath $88.8M (vs. $11.3M YoY), Melinta $12.8M (1M contribution).
- **Cost Management**: Operating expenses $42.6M (vs. $14.1M YoY), with $12.7M one-time acquisition costs.
- **Liquidity**: $55.7M cash at quarter-end; targeting $100M by year-end.
- **Tax Benefit**: $59.7M tax benefit from NOL utilization, supporting future cash savings.

**【Q&A Highlights】**
- **DefenCath Utilization**: LDO customers using 3-4x inventory, faster than expected adoption.
- **Post-TDAPA Strategy**: 
  - Medicare Advantage engagement with real-world evidence data.
  - CMS ESRD rule expected Q1 2026 to determine 2026/27 pricing framework.
- **Melinta Value**: 
  - Stable $30-40M annual revenue from legacy products.
  - Rezeo potential peak sales exceeding DefenCath ($2B TAM).
  - TPN pipeline expansion with 40%+ CLABSI reduction in real-world data.

CorMedix Inc. (CRMD) Q3 2025 Earnings Call Transcript

- **$40M Melinta Deal**: Near-term accretive with $305-$335M 2025 pro forma revenue, $150M+ EBITDA, and $200M+ peak REZZAYO sales potential.
- **DefenCath Momentum**: LDO rollout targets 6,000 patients, Phase III on track for 2026 NDA, and interim RWE data expected by year-end.
- **Financial Strength**: $190M+ cash post-debt offering, Q2 net income $19.8M, and 18% opex growth driven by R&D investment.
- **Strategic Focus**: Synergistic M&A pipeline, no dividend policy, and dual outpatient/inpatient commercial strategy.

**【CEO Summary Section】**
- **Melinta Acquisition**: CorMedix acquired Melinta Therapeutics in a $40 million cash and stock deal, expected to close in September 2025. The transaction is near-term accretive with double-digit EPS accretion in 2026 and pro forma 2025 revenue guidance of $305-$335 million (including $180-$200 million from DefenCath). Near-term operating expense synergies of $33-$45 million are projected, with potential peak sales of REZZAYO's expanded indication exceeding $200 million.
- **DefenCath Progress**: LDO customer initiated DefenCath utilization in early July, targeting 6,000 patients. Phase III study for CLABSI reduction in adults is on track for NDA submission in late 2026/early 2027. Pediatric study enrollment began, with first dosing in August. Interim real-world evidence data with U.S. Renal Care is expected by end-2025.

**【CFO Financial Commentary】**
- **Q2 2025 Results**: Net revenue $39.1 million, net income $19.8 million ($0.29 EPS), up from $14.2 million loss in Q2 2024. Operating expenses rose 18% to $18.3 million, driven by R&D ($2.4 million increase) and G&A ($9.5 million). Cash provided by operations was $30 million, up from $14 million used in Q2 2024. Post-convertible debt offering, cash equivalents stood at $190.7 million as of June 30, 2025.
- **Funding**: $150 million convertible debt priced at 4% coupon and 30% premium, with Deerfield and institutional investors participating. Proceeds will fund Melinta acquisition, with $110 million from CorMedix's balance sheet.

**【Q&A Key Highlights】**
- **DefenCath Guidance Sensitivity**: $180-$200 million range based on LDO rollout visibility, with upside potential as orders materialize. Risks include LDO rollout pace and competitor dynamics.
- **Melinta Portfolio Growth**: REZZAYO's expanded indication for fungal prophylaxis in transplant patients is key growth driver. Existing assets (e.g., VABOMERE, ORBACTIV) have modest growth, while BAXDELA's BARDA collaboration is upside but not core to deal valuation.
- **Integration Strategy**: Synergies will be captured through combined sales force and shared infrastructure. No guidance on integration costs yet, but focus on preserving Melinta's experienced team.
- **Capital Allocation**: Near-term focus on accretive M&A with proven synergies. Dividend policy not prioritized over growth investments.
- **Outpatient vs. Inpatient**: Outpatient DefenCath sales require less touchpoints, while inpatient deployment will leverage Melinta's hospital salesforce. Both channels will be actively managed.

CorMedix, Inc. (CRMD) Q2 2025 Earnings Call Transcript

- **Revenue Beat & Guidance Update**: Q1 $39.1M sales, H1 2025 guidance narrowed to $70M (vs. $62-70M range), driven by U.S. Renal Care inventory normalization.
- **Profitability Breakthrough**: Q1 net income $20.6M vs. $14.5M loss last year, EBITDA $23.6M.
- **Inpatient Growth Accelerating**: April inpatient share 6% vs. Q1 3%, targeting higher pricing opportunity.
- **Clinical Momentum**: Phase 3 CLABSI study first patient dosed, TPN indication peak sales potential $150-200M.
- **LDO Partnership Progress**: Increased pre-implementation activity, targeting mid-2025 start.
- **Reimbursement Strength**: 40% of claims from Medicare Advantage, aligning with 50% MA penetration in ESRD.
- **R&D Investment**: Q1 R&D spend +281% to $3.2M, supporting clinical pipeline expansion.


**【CEO Opening Remarks】**
- Q1 2025 net sales of $39.1 million, in line with pre-announced results.
- Adjusted EBITDA of $23.6 million, slightly above pre-announcement.
- April inpatient hospital orders exceed 6% of shipments, up over 2x Q1 levels.
- Narrowed H1 2025 net revenue guidance to ~$70 million (prior range $62-70M), driven by improved visibility on U.S. Renal Care inventory and utilization trends.
- Optimistic on mid-2025 implementation start with large dialysis operator (LDO), with increased pre-implementation activity observed.
- Inpatient sales team fully operational, targeting ~10% of unit volume TAM but higher pricing potential.

**【CFO Financial Highlights】**
- Q1 2025 net income of $20.6M ($0.32/share), vs. $14.5M loss in Q1 2024.
- Operating expenses +9% YoY to $17.4M, driven by:
  - R&D +281% to $3.2M (clinical trial expenses)
  - G&A +11% to $9.7M (non-cash stock comp)
  - Selling & marketing -29% to $4.5M (timing of outsourced sales force costs)
- Cash position of $77.5M as of March 31, 2025.
- 2025 cash operating expenses guided at $72-78M, up due to R&D spend.

**【Clinical & Commercial Updates】**
- Phase 3 CLABSI study in TPN patients: first site operational, ~150 patients over 12 months, targeting FDA submission end-2026.
- Orphan Drug Designation application filed for TPN indication.
- Real-world evidence study surpassing 2,000 patients, tracking 24-month outcomes.
- Pediatric dialysis study to begin Q3 2025.
- Expanded access program launched for high-risk populations.

**【Q&A Key Takeaways】**
- U.S. Renal Care still >80% of shipments, but smaller customers and inpatients growing faster.
- Inventory lumpiness from U.S. Renal Care resolved by Q3 2025, normalizing to utilization-based ordering.
- 40% of claims from Medicare Advantage plans, aligning with 50% MA penetration in ESRD population.
- Reimbursement negotiations with MA plans expected during TDAPA period.
- Positive provider feedback: smooth workflow integration, clinician adoption, reimbursement support services.

**【Risks & Challenges】**
- Reliance on U.S. Renal Care for >80% of sales.
- TDAPA policy uncertainty beyond 2025.
- Regulatory delays in TPN indication (targeting late 2027 approval).
- Execution risk with LDO implementation timeline.


CorMedix (CRMD)-6 May 25-2025 Q1 Earnings call transcript

- **Record Q4 Profitability**: First profitable quarter with $13.5M net income, driven by DefenCath commercial success.
- **2025 Revenue Guidance**: $50-60M from existing customers in H1, with Q1 sales >$33M.
- **Inpatient Expansion**: New Syneos Health team targeting 10%+ inpatient market share by 2026.
- **Clinical Pipeline Momentum**: TPN Phase 3 study to enroll 150+ patients, with FDA submission by end-2026.
- **Risk Management**: Q2 2025 price erosion expected, but >1 year of inventory cushions supply chain risks.
- **Policy Tailwind**: CMS policy change removes TDAPA penalty, enabling 15-20% patient growth at key customer.


**【CEO Summary Section】**
- **Q4 and Full Year 2024 Financial Highlights**: Net revenue of $31.2 million (Q4) and $43.5 million (FY2024), both exceeding Wall Street consensus. First profitable commercial quarter with net income of $13.5 million and adjusted EBITDA of $15.3 million.
- **2025 Outlook**: Projected net revenue from existing customers for H1 2025 is $50-60 million, with $33 million+ expected in Q1. Price erosion expected to begin in Q2 2025, driven by government ASP adjustments.
- **Inpatient Segment Expansion**: New Syneos Health field team nearly fully staffed, targeting VA facilities and academic medical centers. Inpatient sales expected to contribute meaningfully by end of 2025.
- **Clinical Pipeline Progress**: Phase 3 TPN study to begin Q2 2025, targeting FDA approval by late 2027. Expanded access program for high-risk populations to start Q2 2025.

**【CFO Financial Commentary】**
- **Q4 2024 Financials**: GAAP net income of $13.5 million, up from $14.8 million loss in Q4 2023. Operating expenses increased 9% to $17.1 million, driven by S&M and G&A costs. R&D expense decreased 26% to $1.7 million post-DefenCath approval.
- **Full Year 2024 Cash Position**: $51.7 million in cash as of Dec 31, 2024. Anticipated Q1 2025 cash of $75+ million from collections and ATM proceeds. 2025 cash operating expenses guided at $72-78 million, up 28% YoY due to clinical trial spending.

**【Key Q&A Highlights】**
- **LDO Customer Progress**: Contracted LDO delayed implementation due to operational constraints, but CorMedix providing extensive support. Mid-2025 implementation remains target.
- **Price Erosion Impact**: Q2 2025 ASP decline of ~1%, with potential for higher erosion in later quarters. Channel inventory management critical to mitigate impact.
- **Manufacturing Capacity**: >1 year of finished goods inventory at current run rate. Raw material suppliers (heparin, taurolidine) secure with multiple lots on order.
- **Policy & Reimbursement**: CMS policy change in Nov 2024 removed TDAPA penalty, driving 15-20% patient lift at U.S. Renal Care. Third-party hub assists providers with claims navigation.
- **Administrative Changes**: New administration initiatives could create opportunities for cost reduction and innovation incentives, aligning with DefenCath's infection prevention value proposition.


Actual								-0.21	-0.14	-0.22	-0.19	-0.2	-0.12	-0.22	-0.2	-0.18	-0.19	-0.17	-0.2	-0.24	-0.25	-0.17	-0.26	-0.25	-0.25	-0.05	0.22	0.3	0.29	1.26	0.16
Forecast								-0.23	-0.24	-0.255	-0.22	-0.184	-0.18	-0.1767	-0.2333	-0.22	-0.2067	-0.23	-0.1869	-0.2009	-0.2392	-0.21	-0.2011	-0.2769	-0.251	-0.122	0.1317	0.26	0.1871	0.6343	0.8162
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+8.70%	+41.67%	+13.73%	+13.64%	-8.70%	+33.33%	-24.50%	+14.27%	+18.18%	+8.08%	+26.09%	-7.01%	-19.46%	-4.52%	+19.05%	-29.29%	+9.71%	+0.40%	+59.02%	+67.05%	+15.38%	+55.00%	+98.64%	-80.40%

Actual	--	--	--	--	--	--	--	74.05K	16.44K	93.02K	55.71K	88.26K	8.19K	38.09K	56.40K	7.64K	21.25K	6.82K	29.70K	0	0	0	0	0	806.12K	11.46M	31.21M	39.08M	39.74M	104.30M	128.60M
Forecast	--	--	--	--	--	--	--	250.00K	117.50K	28.75K	46.25K	39.60K	43.25K	20.00K	19.00K	25.00K	0	0	2.33K	0	0	0	-333.33K	0	1.67M	10.35M	27.28M	36.95M	35.08M	86.02M	127.02M
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-70.38%	-86.01%	+223.55%	+20.46%	+122.88%	-81.06%	+90.44%	+196.83%	-69.46%	0.00%	0.00%	+1173.12%	0.00%	0.00%	0.00%	+100.00%	0.00%	-51.65%	+10.73%	+14.42%	+5.78%	+13.29%	+21.25%	+1.24%

CRMD

CRMD fundamentals

CRMD Q4 2025 Earnings

Earnings Call

You can ask Aime

CRMD

CRMD fundamentals

CRMD Q4 2025 Earnings

Earnings Call

CRMD Earnings Call Summary for Q4/20258:30 AM on Mar 5, 2026

CRMD Earnings Call Summary for Q3/20258:30 AM on Nov 12, 2025

CRMD Earnings Call Summary for Q2/20258:30 AM on Aug 7, 2025

CRMD Earnings Call Summary for Q1/20258:30 AM on May 6, 2025

CRMD Earnings Call Summary for Q4/20248:30 AM on Mar 25, 2025

You can ask Aime